Alpha Tau's Promising Results: A Boost for Investors at J.P. Morgan Healthcare Conference

Alpha Tau Medical, developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Uzi Sofer, and CFO, Raphi Levy, will deliver a corporate overview and update on January 16, 2025, from 9:45 AM to 10:25 AM PT at the Westin St. Francis in San Francisco. The presentation will highlight recent company achievements and upcoming data milestones, as well as strategic partnerships and collaborations that showcase Alpha Tau's growth potential. Institutional investors can schedule one-on-one meetings with the executives through their J.P. Morgan representatives, and a webcast of the presentation will be available on the company's website in the Investor Relations section.

Alpha Tau's recent interim results in treating advanced pancreatic cancer have significantly boosted investor interest and the company's valuation. The successful delivery of Alpha DaRT sources in all five cases, with no product-related serious adverse events, and the first partial response observed, have demonstrated the therapy's potential. This positive data has likely contributed to Alpha Tau's stock price increase, reflecting growing confidence in the company's innovative alpha-radiation cancer therapy.

The company's promising results in pancreatic cancer treatment, combined with its Breakthrough Device Designation for recurrent GBM treatment, signal a potential shift in the cancer treatment landscape. Alpha Tau's Alpha DaRT technology, which enables highly potent and conformal alpha-irradiation of solid tumors, could offer a new, targeted approach to cancer treatment. This could pose a competitive threat to existing radiation therapies, such as proton therapy and brachytherapy, which have limitations in terms of precision and side effects. Moreover, Alpha Tau's focus on hard-to-treat indications and combination therapies could expand the market for its technology, potentially attracting investors seeking exposure to innovative cancer treatments.

As Alpha Tau presents at the J.P. Morgan Healthcare Conference, investors will be eager to learn more about the company's recent progress and future plans. The presentation is an opportunity for Alpha Tau to showcase its innovative technology and the promising results it has achieved in treating advanced pancreatic cancer. With a strong pipeline of upcoming data milestones and strategic partnerships, Alpha Tau is well-positioned to continue its growth and attract investor interest.



In conclusion, Alpha Tau's recent interim results in pancreatic cancer treatment have significantly boosted investor interest and the company's valuation. As the company presents at the J.P. Morgan Healthcare Conference, investors will be eager to learn more about its innovative technology and promising results. With a strong pipeline of upcoming data milestones and strategic partnerships, Alpha Tau is well-positioned to continue its growth and attract investor interest in the cancer treatment market.